RT Journal Article
SR Electronic
T1 CAR T cell therapy in B-cell acute lymphoblastic leukaemia: Insights from mathematical models
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.18.20038257
DO 10.1101/2020.03.18.20038257
A1 Odelaisy León-Triana
A1 Soukaina Sabir
A1 Gabriel F. Calvo
A1 Juan Belmonte-Beitia
A1 Salvador Chulián
A1 Álvaro Martínez-Rubio
A1 María Rosa
A1 Antonio Pérez-Martínez
A1 Manuel Ramirez-Orellana
A1 Víctor M. Pérez-García
YR 2020
UL http://medrxiv.org/content/early/2020/03/23/2020.03.18.20038257.abstract
AB Immunotherapies use components of the patient immune system to selectively target cancer cells. The use of CAR T cells to treat B-cell malignancies – leukaemias and lymphomas– is one of the most successful examples, with many patients experiencing long-lasting complete responses to this therapy. This treatment works by extracting the patient’s T cells and adding them the CAR group, which enables them to recognize and target cells carrying the antigen CD19+, that is expressed in these haematological tumors.Here we put forward a mathematical model describing the time response of leukaemias to the injection of CAR T-cells. The model accounts for mature and progenitor B-cells, tumor cells, CAR T cells and side effects by incorporating the main biological processes involved. The model explains the early post-injection dynamics of the different compartments and the fact that the number of CAR T cells injected does not critically affect the treatment outcome. An explicit formula is found that provides the maximum CAR T cell expansion in-vivo and the severity of side effects. Our mathematical model captures other known features of the response to this immunotherapy. It also predicts that CD19+ tumor relapses could be the result of the competition between tumor and CAR T cells analogous to predator-prey dynamics. We discuss this fact on the light of available evidences and the possibility of controlling relapses by early re-challenging of the tumor with stored CAR T cells.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work has been partially supported by the Junta de Comunidades de Castilla-La Mancha (grant number SBPLY/17/180501/000154), the James S.Mc. Donnell Foundation (USA) 21st Century Science Initiative in Mathematical and Complex Systems Approaches for Brain Cancer (Collaborative award 220020450), Junta de Andalucía group FQM-201, Fundación Española para la Ciencia y la Tecnología (FECYT, project PR214 from the University of Cádiz) and the Asociación Pablo Ugarte (APU). OLT is supported by a PhD Fellowship from the University of Castilla-La Mancha research plan.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe manuscript has not data.